Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In Vivo Therapy with M2e-Specific IgG Selects for an Influenza A Virus Mutant with Delayed Matrix Protein 2 Expression.

mBio - 31 Aug 2021

Van den Hoecke Silvie, Ballegeer Marlies, Vrancken Bram, Deng Lei, Job Emma R, Roose Kenny, Schepens Bert, Van Hoecke Lien, Lemey Philippe, Saelens Xavier

Abstract excerpt

The ectodomain of matrix protein 2 (M2e) of influenza A viruses is a universal influenza A vaccine candidate. Here, we report potential evasion strategies of influenza A viruses under in vivo passive anti-M2e IgG immune selection pressure in severe combined immune-deficient (SCID) mice. A/Puerto Rico/8/34-infected SCID mice were treated with the M2e-specific mouse IgG monoclonal antibodies (MAbs) MAb 65 (IgG2a)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Viral
Share to High-Throughput Nucleotide Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Evasion

Share to Immunoglobulin G

Share to Influenza A virus

Share to Mice, Inbred BALB C

Share to Mice, SCID

Share to Viral Matrix Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 34253060
DOI: 10.1128/mBio.00745-21
PMCID: PMC8406285

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In Vivo Therapy with M2e-Specific IgG Selects for an Influenza A Virus Mutant with Delayed Matrix Protein 2 Expression.PMID 34253060Read ↗

Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2.Semantic proximity Read ↗

A Low-Dose Triple Antibody Cocktail Against the Ectodomain of the Matrix Protein 2 of Influenza A Is A Universally Effective and Viral Escape Mutant Resistant Therapeutic AgentSemantic proximity Read ↗

Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1Semantic proximity Read ↗

Structure of the Extracellular Domain of Matrix Protein 2 of Influenza A Virus in Complex with a Protective Monoclonal AntibodySemantic proximity Read ↗

SARS-CoV-2 evolution and evasion from multiple antibody treatments in a cancer patientSemantic proximity Read ↗

Multiple layers of innate immune response antagonism of SARS-CoV-2Semantic proximity Read ↗

VLPs Containing Stalk Domain and Ectodomain of Matrix Protein 2 of Influenza Induce Protection in MiceSemantic proximity Read ↗

Identification of key host genes for influenza A virus in avian cells using a genome-wide CRISPR-Cas9 screenSemantic proximity Read ↗

Innate and adaptive immune responses against Influenza A Virus: Immune evasion and vaccination strategiesSemantic proximity Read ↗

A Perspective on the Structural and Functional Constraints for Immune Evasion: Insights from Influenza Virus.Semantic proximity Read ↗

Comparing Influenza Virus Biology for Understanding Influenza D VirusSemantic proximity Read ↗

A VSV-vector vaccine simultaneously targeting H5N1 hemagglutinin (HA) and matrix protein 2 (M2) induces robust neutralizing and ADCC antibody responses and provides full protection against lethal H5N1 infection in a mouse modelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.